Abstract: A complex comprising a carrier containing a plasma-derived protein or serum-derived protein solidified by denaturation coagulation, and a protein having a peroxidase-like activity and carried by the carrier, which has such high effectiveness that it can strongly stimulate an antigen-presenting cell, and can be used as a highly safe immunostimulant with reduced toxicity to living bodies.

Abstract: Disclosed are means, methods and treatments of Leigh Syndrome, using mesenchymal stem cells. In one particular embodiment, mesenchymal stem cells are administered for the purposes of reducing disease progression, and reversing disease. Said mesenchymal stem cells may be generated according to the invention, by selection of markers specifically upregulated or downregulated on enhanced cells as compared to majority of mesenchymal stem cells. The invention further provides means of co-administration of mesenchymal stem cells with lysates, conditioned media, or exosomes of said mesenchymal stem cells to enhance therapeutic activity.

Abstract: A tumor vaccine for use in combination with a photodynamic therapy for a malignant tumor, which contains a tumor antigen derived from a tumor tissue separated from a patient to whom the photodynamic therapy is to be applied.

Abstract: A complex comprising a carrier containing a plasma-derived protein or serum-derived protein solidified by denaturation coagulation, and a protein having a peroxidase-like activity and carried by the carrier, which has such high effectiveness that it can strongly stimulate an antigen-presenting cell, and can be used as a highly safe immunostimulant with reduced toxicity to living bodies.

Abstract: Disclosed are means, methods and compositions of matter useful for treatment of spinal muscular atrophy. In one embodiment, stem cells of the mesenchymal type are modified to enhance anti-inflammatory and regenerative potential in a manner to prevent disease, inhibit progression and/or reverse existing disease. In other embodiments combinations of mesenchymal stem cells together with extracts and/or products derived from said mesenchymal stem cells are administered for prevention, inhibition of progression and/or reversion of spinal muscular atrophy.

Abstract: Disclosed are protocols, isolation means, and compositions of matter useful for identifying mesenchymal stem cells possessing enhanced clinical activity. In one embodiment, markers associated with said enhanced mesenchymal stem cell activity are utilized to identify donors whose mesenchymal stem cells possess superior efficacy compared to mesenchymal stem cells from donors who lack said markers associated with said enhanced efficacy. In one embodiment, said markers are utilized to select for mesenchymal stem cells possessing enhanced efficacy from in vitro cultures. In another embodiment, surfaces markers associated with said markers associated with enhanced efficacy are utilized to positively select for cells possessing enhanced efficacy. In another embodiment, the invention teaches markers whose expression is correlated with negative efficacy. Said markers can be utilized to exclude mesenchymal stem cell donors, or in vitro generated and/or isolated mesenchymal stem cells prior to clinical use.

Abstract: An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity.

Abstract: An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity.

Abstract: A tumor vaccine which comprises a microparticle or a lysate prepared from a solidified tumor material selected from the group consisting of a tumor tissue, a tumor cell, and a component thereof, and at least one cytokine and/or cytokine-inducing agent (e.g., a granulocyte-macrophage-colony stimulating factor and/or interleukin-2 and the like), and optionally an adjuvant. The vaccine can be easily prepared and widely applied for prevention of recurrence, inhibition of metastasis and therapeutic treatment regardless of a type of a tumor, and has excellent antitumor effect.